Skye Bioscience, Inc. has been advised by its contract manufacturer (CMO) that it has completed the production of SBI-100 Ophthalmic Emulsion (SBI-100 OE) for Skye's Phase 1 clinical trial. The final drug product will be released and available for clinical use in October, following receipt of acceptable results from quality and analytical testing that has been initiated.